key: cord-1006398-h0ppiyro
authors: Xue, Mingshan; Zeng, Yifeng; Qu, Hui-Qi; Zhang, Teng; Li, Ning; Huang, Huimin; Zheng, Peiyan; Hu, Haisheng; Zhou, Luqian; Duan, Zhifeng; Zhang, Yong; Bao, Wei; Tian, Li-feng; Hakonarson, Hakon; Zhong, Nanshan; Zhang, Xiaohua Douglas; Sun, Baoqing
title: Heparin-binding protein levels correlated with aggravation and multi-organ damage in severe COVID-19
date: 2020-11-12
journal: ERJ Open Res
DOI: 10.1183/23120541.00741-2020
sha: c2d9b7c0c1eae4d5279f0b8b4e2fd5f3550bec0b
doc_id: 1006398
cord_uid: h0ppiyro

BACKGROUND: Critically ill COVID-19 patients may suffer persistent systemic inflammation and multiple organ failure, leading to a poor prognosis. RESEARCH QUESTION: To examine the relevance of the novel inflammatory factor heparin-binding protein (HBP) in critically ill COVID-19 patients, and evaluate the correlation of the biomarker with disease progression. STUDY DESIGN AND METHODS: Eighteen critically ill COVID-19 patients who suffered from respiratory failure and sepsis, including 12 cases who experienced a rapidly deteriorating clinical condition and 6 cases without deterioration, were investigated. They were compared with 15 age- and sex- matched COVID-19 negative patients with respiratory failure. Clinical data were collected and HBP levels were investigated. RESULTS: HBP was significantly increased in critically ill COVID-19 patients following disease aggravation and tracked with disease progression. HBP elevation preceded the clinical manifestations for up to 5 days and was closely correlated with patients’ pulmonary ventilation and perfusion status. INTERPRETATION: HBP levels are associated with COVID-19 disease progression in critically ill patients. As a potential mediator of disease aggravation and multiple organ injuries that are triggered by continuing inflammation and oxygen deficits, HBP warrants further study as a disease biomarker and potential therapeutic target.

The global pandemic of Coronavirus disease starting in December 2019 was caused by a novel Coronavirus named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the International Committee for Virus Taxonomy [1] . Sequencing analysis of the virus genome indicates 79.5% gene sequence homology with SARS-CoV from 2002, implying that the pathogenic processes underlying severe pneumonia may share similarities among both viruses [1] [2] [3] . The pathogenesis of COVID-19 has been unfolding, and clinicians are starting to focus on rehabilitation and treatment of the associated inflammatory sequelae [4] . Consequently, several studies have reported that some SARS-CoV-2-positive patients with stable clinical conditions and nucleic acid tests converted to negative may suddenly worsen or even die during the post-viral infection stage [5] [6] [7] . While false negative testing, as well as underlying chronic diseases exacerbated by the stress of infection, could be contributing factors, an inflammatory condition caused by SARS-CoV-2 may persist after viral RNA is no longer detectable. A secondary inflammatory storm may occur during this stage of infection, causing multi-organ failures [5, [8] [9] [10] [11] [12] . The aggravation of such inflammatory processes during otherwise a clinically stable state was also reported in 2002 during SARS as well as in some cases of severe community-acquired pneumonia [13] [14] [15] . Therefore, new knowledge about the mechanisms of the worsening of COVID-19 patients is warranted to establish interventions that may significantly improve the prognosis [9, 16] . Biomarkers associated with the disease aggravation as well as potential therapeutic targets would be extremely valuable in this respect.

Heparin-binding protein (HBP), also known as azurocidin or cationic antimicrobial protein of 37-kDa [17] , is stored in azurophilic granules and secretory vesicles of polymorphonuclear neutrophils (PMN), at the cell membrane and in the azurophilic granules [18] . Endothelial cells are the primary targets of HBP released in the circulation and this protein plays a major role in the mechanism of capillary leakage, while it amplifies inflammatory effects by inducing cytoskeletal rearrangement and resulting in increased permeability of the vascular endothelial barrier [17, 19] . Antigens, inflammatory factors, cytokines and enzymes can stimulate PMN to release HBP by exocytosis [20, 21] . Studies in sepsis have indicated that the sensitivity and specificity of HBP are varied, compared to C-reactive protein (CRP) or procalcitonin (PCT), as an independent predictor of clinical outcome in severe infection [22, 23] . Our recent study highlighted the role of IgA deposition and its mediated vasculitis in severe COVID-19 [24] . Considering the major role of HBP in endothelial dysfunction and systemic vasculitis in severe infections, we hypothesized that elevated HBP might mediate the pathogenesis of severe COVID-19 aggravation. The goal of this study was to establish whether HBP is a useful biomarker and is associated with disease aggravation for those patients eventually requiring advanced treatment options. HBP could serve as a potential therapeutic target for patients who are at risk of developing systemic multiple organ failures, with improvement in the patient prognosis and to prevent death in severely ill patients.

According to the latest international diagnostic criteria for COVID-19 [25] , 18 patients with critical respiratory failure and clinical presentation of a viral-like sepsis were included in this study conducted at the First Affiliated Hospital of Guangzhou Medical University. Exclusion criteria were a history of chronic liver or kidney disease.

Among the 18 patients, two major clinical patterns were seen, i.e. 12 patients met the characteristics of a clinical stable period before exacerbations of COVID-19 rather than secondary nosocomial infections in the clinical stable period, while 6 other patients had been without aggravation. We referred to the studies by Blum et al 2015 [26] and Paul et al 2018 [27] for the definition of clinical stable period of severe infections, characterized by: vital signs stable for more than 24 hours (below 37.5 degrees Celsius, heart rate less than 100 per minute, respiratory rate less than 24 per minute), no shock, no respiratory symptoms such as dyspnea and chest tightness. The definition of the clinical deterioration of the disease was based on the clinical studies by Vultaggio et al. [28] and Yang et al. [29] , i.e. meeting one of the following criteria after a clinical stable period: (1) death during hospitalization [28] ; (2) transferred to ICU due to severe exacerbation of respiratory failure requiring invasive support measures to correct hypoxemia [28] ; (3) aggravated respiratory failure without requiring invasive ventilation support [28] ; (4) respiratory distress (respiratory rate ≥ 30/min) [29] ; (5) resting oxygen saturation ≤ 93% [29] ; (6) arterial oxygen partial pressure (PaO2)/ inhaled oxygen fraction (FiO2) ≤ 300 mmHg [29] . Considering the possibility of false negative nucleic acid tests in COVID-19 patients and differences across different sites, we assessed disease progression by a comprehensive evaluation involving three clinicians and three investigators.

According to the previous studies, most COVID-19 patients with sepsis involve nosocomial infections [30, 31] . In line with the purpose of this study on HBP and COVID-19 aggravation by persistent inflammation, it is of great importance to exclude patients aggravated by nosocomial infection. Therefore, we emphasized that no new pathogens were detected in sputum and midstream urine to exclude patients with nosocomial infection.

Fifteen age-and sex-matched COVID-19 negative patients with respiratory failure were included for comparison. Clinical information was extensively documented, and the level of HBP was assessed in each participant. This study lasted for 125 days. Two time points were set, respectively: admission point and clinically stable point. The different clinical status/periods in each patient were comprehensively assessed and distinguished.

Fresh venous blood was collected from the participants and placed in an upright tube for 1-2 hours, then centrifuged at 3000rpm for 15 minutes. Plasma samples with sodium citrate anticoagulation (1:9) were tested. When separating plasma, care was taken not to aspirate white blood cells layer to avoid the releasing of high levels of HBP. HBP is easily degraded (Half-life is 1h), therefore, all samples in the study were detected immediately after collection during 1h. Jet-istar 3000 automatic analyzer (JOINSTAR BIOMEDICAL TECHNOLOGY CO., LTD, Zhejiang, China) was used to assess 50 µl of sample, which was incubated for 18 min, and the HBP level detected by the dry fluorescent immunoassay methodology.

Lungs were imaged to acquire posteroanterior oblique and lateral views (PA&LAT) and quantitative high resolution computed tomography (HRCT) analysis was undertaken. Care was taken for chest PA&LAT examinations to ensure that the patient's respiratory cycle did not blur the image by rapid exposure at inspiration (0.08s). The centerline of the PA plate was aligned with the 5th dorsal thoracic vertebra, while the centerline of the LAT plate to the lateral thoracic wall at the 5th thoracic vertebra. The cassette was placed at 3 cm above the shoulder on the opposite side. The field covered the costophrenic angle. Major evaluations covered pulmonary markings, substantive area, cardiac shadow area and the costophrenic angle. The percentage of total lung area affected by the infection was adopted to evaluate the area of pulmonary involvement. HRCT was set at a slice thickness of 1.0 mm. The quantitative analysis system was used to evaluate the area of solid shadow, patch shadow and fibrous strip shadow. Additionally, we also acquired abdominal HRCT images to evaluate organ function during the study period (i.e. with abnormally low or high density).

Continuous variables were expressed as median and interquartile range (IQR). Nonparametric testing (Mann-Whitney test) was used to analyze differences between groups. Correlation was assessed using Spearman correlation coefficient. A value of p<0.05 was considered statistically significant. Cross-correlation function (CCF) testing was applied to explore correlations between different indexes and HBP levels [32] . The phase relationship between different index trends and HBP trends was examined by determining the time lag at which the value of the CCF was maximal [32] . Standardized method was adopted as , i.e. 

As shown in Table 1 , HBP levels were significantly higher in 18 critical COVID-19 patients compared to patients with other respiratory failure. CRP and PCT were also higher in COVID-19 patients. Although the white blood cell and neutrophil counts were higher in COVID-19, the lymphocyte count was lower. The D-Dimer level was significantly higher in COVID-19, suggesting extensive disturbances to the microcirculation despite the absence of hypotensive shock and diagnostic criteria for disseminated intravascular coagulation (DIC) not being met. This finding of D-Dimer change has also been observed by Li et al. 2020 [33] .

In Table 2 , we show the dynamic changes of various indicators in the 12 patients with aggravation in the process of the disease. Continuous high levels of HBP were seen in these patients with further increase observed with the disease aggravation. In contrast, the 6 patients without aggravation had decreasing levels of HBP with the stabilization of the disease ( Table 3) .

As shown, there is significant correlation between HBP and PMN in aggravation group (P<0.05, r=0.35), however in remission group there did not show significant correlation ( Figure 1A) . Although the two mechanisms are closely related, they do not look completely parallel from the data. In contrast, the HBP level in the case group with aggravation showed a significant upward trend since the clinical stable period, which peaked on the 10th day after the aggravation period, and it began to decline at the 20th day as the disease getting under control. As patients with severe COVID-19 who developed aggravation had the disease progression at varied time points, we used time ranges to indicate aggravation. PMN showed a similar trend, but the increase was not as significant as for HBP and the decrease at later time points was greater. In contrast, the HBP level of the patients with remission of the disease showed a significantly downward trend. In these patients, the HBP levels were significantly correlated with CRP and PCT (r=0.463, 0.497, respectively, with both P<0.001).

Comparing HBP levels with an inflammatory index composed of IL-2, IL-4, IL-6, IL-10, TNF-α and IFN-γ ( Figure 1B and Supplementary Table 1) revealed that IL-6 showed the most significant increase over the progress of disease. We further projected these variables onto the plane of the Inflammatory Indexes and HBP to enable more intuitive visualization of the linear relationship, and found that IL-6 had a strikingly positive correlation with HBP (r=0.693, P<0.001), and also a significant correlation with disease duration (P<0.001).

Activated partial thromboplastin time (APTT), which closely tracks endogenous coagulation, is longer in the aggravation period than the clinical stable period (Supplementary Table 2 ). D-dimer was markedly increased in the aggravation period in clinical stable period and correlated with HBP. However, patients' clinical manifestations did not meet the diagnostic criteria for DIC.

We compared data on the changes of pulmonary effusion from HRCT and Chest PA&LAT at the admission time point, with the subsequent trajectory of HBP in different clinical periods (Figure 2A) . The aggravation period after the clinical stable period shows that the increase of HBP occurs earlier, at around 35-40 days, while HRCT and Chest PA&LAT peak at around 45 days. After calculating the cross-correlation function of HRCT and Chest PA&LAT ( Figure 2B and 2C), we found that the strongest correlation with HBP was when HRCT and Chest PA&LAT lagged by 5 days. Thus, HBP rises and reaches a peak around 5 days prior to HRCT and Chest PA&LAT. Our further analysis showed that HBP was correlated with PA-aDO2, Qsp, Spiro-Index and OI (Supplementary Figure 2) .

The overall levels of AST, CK, CK-MB, cTnI and Mb increased at 35-45 days at the aggravation period after clinical stable period (Supplementary Table 3 Figure 3A ). During this period, the Pro-BNP of the patients was 2479 (95% CI: 603.4, 3379) pg/mL, which was significantly higher than healthy level (<50pg/ml). No patients had a significant decrease in urine output. Imaging indicated that one patient had a pericardial effusion, but no enlargement in cardiac shadow or abnormalities in cardiovascular performance. Compared with the changes of HBP levels (peaking at [35] [36] [37] [38] [39] [40] , there was a time lag in the changes of the above five markers. After calculating the cross-correlation (Supplementary Figure 3B) , it was found that once again a 5 days lag yielded the strongest correlation with HBP peaking about 5 days earlier than AST, CK, CK-MB, cTnI and MB.

We selected BUN, Cr and K + as indicators to reflect kidney function. In the aggravation stage, BUN and Cr but not K + showed a significant upward trend (Supplementary Table 4 and Supplementary Figure 4A) . During this period, abdominal CT showed no obvious abnormalities in the kidneys. CCF analysis (Supplementary Figure 4B) showed a strong positive correlation between BUN, Cr and HBP, indicating that changes in BUN and Cr mirror those of HBP, again with a 5 days time lag. For K + , values held steady without an obvious rise or peak, so the correlation between K + and HBP is very weak.

The AST/ALT ratio, as an indicator reflecting liver injury, showed an upward trend starting at 35 days, and reached the peak of >3 at 40 days (Supplementary Figure 4A) , indicating more severe hepatocyte destruction. However, during this period, abdominal CT indicated no new abnormal low-density lesions in the liver.

In the severe COVID-19 patients, a total of 7 patients exhibited a change from negative to positive during the stable period. We summarized the nucleic acid test results at different times and at different sites in the patient population in the study (Supplementary Table 5 ). Unsurprisingly, we did not find a correlation between HBP and these test results, thus concluded that the increase in HBP was unrelated to the reversion of RNA positivity.

Respiratory symptoms are the main manifestation of COVID-19, and severe diffuse alveolar epithelial injury is one of the major pathological features [34] . In severely ill patients, pulmonary exudation is significantly increased and abnormal dilatation of the pulmonary vessels at the sites of lesions is commonly observed [35] . However, extrapulmonary organs such as the liver, kidney and heart, may also suffer direct or secondary damage [36] . SARS-CoV-2 can trigger inflammatory storms affecting perfusion, resulting in multiorgan dysfunction, which has been reported in imaging, biopsy and autopsy studies -despite there being no direct evidence of viral infection in these extrapulmonary organs [36] [37] [38] . At the clinical stable stage of severe COVID-19 with respiratory failure combined with sepsis, some patients aggravated and suffered multiple organ injuries. Studies have reported that systemic inflammatory responses are stronger in the elderly, and those with weakened adaptive immunity and malnutrition may have more severe clinical manifestations and more likely to relapse without again testing positive for the virus, due to non-infection-related secondary inflammation, which is one of the leading causes of death during stable period and is comparable to the risk of sudden cardiac death from COVID-19 [39] [40] [41] [42] . We speculated that it may be caused by persistent inflammation triggered by SARS-CoV-2. Pathogens and their fragments released after tissue destruction are recognized as foreign bodies. Immune dysfunction may lead to clinical deterioration. Excessive activation of innate immunity aggravates the damage to tissues and organs, reinforcing a vicious cycle [43] .

In this study, we found that the novel inflammatory factor HBP was closely correlated with the aggravation of severe COVID-19 with respiratory failure, as well as its correlation with levels of inflammatory markers, coagulation abnormalities, and pulmonary injuries.

HBP is stored in vesicles in PMN near the cell membrane and is released when they are activated. In the present study, correlations of the changes of HBP levels and PMN with the exacerbation of disease in the stable stage were consistent; both began to rise at 30 days and peaked at 35 days. Correlation analysis of the six inflammatory factors measured in this study showed that IL-6 levels were significantly increased and related to HBP, and the two factors paralleled disease progression over time. The level of IL-6 can be elevated in the early stages of an inflammatory storm, after which CRP, PCT and amyloid protein increase, all positively correlated with the progression of inflammation and inhibition of PMN apoptosis [44] . Studies have shown that IL-6 amplifies the inflammatory response and enhances PMN production, and activates them to release HBP [45] [46] [47] .

Pulmonary exudation is significantly increased in COVID-19 patients, which is closely related to the mechanism of pulmonary vascular leakage activated by HBP (Supplementary Figure 5) . Vascularity and neutrophil exosmosis and aggregation can further aggravate systemic inflammatory responses, and finally exacerbate sepsis. Moreover, Albarello et al. [48] found local abnormal dilatation of blood vessels in the lung exudation area (not caused by microthrombi). Pulmonary blood flow perfusion imbalance is also one of the causes of hypoxemia, but the mechanism is unknown. We made a further speculation according to the research form Morsing et al. [49] and Lauritzen et al. [50] that the local release of vasodilatory substances such as histamines may be caused by leukocyte extravasation which is activated by endothelial cytoskeletal reorganization, in turn activated by HBP, leading to pulmonary vascular dilatation and tortuosity when under the inflammatory environment. Song et al. [51] found that increasing HBP damages surface polysaccharides of epithelial cells, and activates endogenous coagulation mechanisms, causing APTT prolongation and Ddimer rises.

The cytoskeleton consists of microfilaments, microtubules, and intermediate fibers: the microfilaments are composed of actin, myosin, and actin-binding proteins [52] . HBP binds to and internalizes the surface polysaccharide receptor of endothelial cells to activate protein kinase C (PKC) and Pho kinase (PhoK) [53, 54] . PKC in turn activates voltage-gated calcium channels, facilitating Ca2+ influx, increasing concentrations of which result in altered actin alignment [54] . PKC also phosphorylates cytoskeletal proteins directly and causes contraction. Rho can promote myosin light chain (MLC) phosphorylation and also initiate cytoskeletal rearrangement [55] . Eventually, gap formation between otherwise tightly adhering endothelial cells causes increased permeability and thus capillary leakage, allowing neutrophil migration (Supplementary Figure 5) .

Additionally, we identified a dynamic correlation of pulmonary effusion lesions with HBP, HRCT and Chest PA&LAT. It was found that HBP elevation preceded the progression of pulmonary lesions by 5 days, and was significantly correlated with changes in pulmonary effusion area. Therefore, from the imaging perspective, the elevation of HBP precedes the pulmonary lesion progression. Compared with the commonly used inflammatory factors CRP, PCT and amyloid, HBP may not only reflect the level of inflammation as a biomarker in evaluating severe patients, but also be an important mediator in the mechanism of inflammation progression.

Severe hypoxemia is prevalent in patients with severe COVID-19, and acute diffuse respiratory distress syndrome is a major factor contributing to a poor prognosis [56] . In the present study, HBP levels were found to be significantly correlated with intrapulmonary shunt volume, arterial alveolar oxygen differential, respiratory index and oxygenation index. Under the influence of capillary leakage syndrome and vascular endothelial cell destruction caused by pathological factors including HBP, the respiratory membrane and pulmonary blood perfusion are affected, eventually leading to the decline of pulmonary ventilation function [57, 58] . Hence, we found that HBP is closely related to pulmonary ventilation in COVID-19, parallel to the degree of hypoxia in this study. This close correlation also highlights the association between HBP and abnormal intrapulmonary shunting.

Extrapulmonary organ injuries were commonly seen in this study. Markers of myocardial cell damage increased in the present study, with pericardial effusion seen in one patient. Inciardi et al. [59] and Zheng et al. [60] both reported myocarditis as manifestations that may be evidence of extrapulmonary organ involvement in COVID-19, accompanied by an increase in myocardial indicators. Here, we found peak values of AST/ALT >3. Zhang et al. [36] found that liver injury was more common in patients with severe than mild COVID-19 and reported a significant increase in AST in severely ill patients, consistent with the results of this study. In the stage, hepatocyte mitochondria were damaged, with a large amount of AST released and the AST/ALT ratio remarkable increased. A ratio >3 indicates serious liver tissue damage. Additionally, BUN and Cr were also increased, and urine occult blood and protein were positive; two severely ill patients were diagnosed with acute kidney damage. Renal perfusion is affected by hypoxia and systemic inflammation, resulting in glomerular filtration dysfunction. Cheng et al. [60] reported that severe COVID-19 patients can exhibit secondary renal dysfunction with accompanying fluid retention resulting in some developing AKI.

However, our study did not find a significant decrease in urine volume or electrolyte imbalance such as for K + . Correlation between HBP levels and these extrapulmonary organ injuries seen in this study might be due to the consequences of COVID-19 aggravation. Inflammation and hypoxia of lung injuries may be the direct causes.

In severely ill COVID-19 patients of our hospital, the viral RNA test may convert to negative. In these patients however, sudden exacerbation caused by persistent inflammation in stable stage may still happen and lead to multi-organ damages. The absence of viral inclusion bodies in the heart, liver, and kidney suggests that direct viral infection may not be the cause, consistent with several other studies [36, 59] . In contrast, elevated HBP in these patients were highlighted as the potential culprit. Nonetheless, we also found that some indicators reflecting levels of organ injury level did not decrease even when inflammation was controlled.

Akbarshakh et al. [61] postulated that this persistent state of organ injury may last for a long time, and that especially for severe COVID-19, organ damage may not improve in the short term (by days), so early treatment interventions would significantly improve the prognosis. The critical issue is to find the ideal therapeutic targets. Considering the potential pathological roles of HBP in severe COVID-19, its value as a therapeutic target is highlighted [62] , e.g. by heparin-based therapy [63] . This is especially important when considering that coagulation disorders have been suggested an important issue in COVID-19 [64] . Investigation on HBP for its therapeutic value is thus warranted.

The correlation of HBP with COVID-19 aggravation suggests its key role in systemic inflammation in patients with severe COVID-19. Our longitudinal analysis revealed that HBP increased around 5 days preceding any imaging features of organ dysfunction. We therefore propose that HBP monitoring can be a useful biomarker for COVID-19 aggravation and multiple organ injuries as sequelae of SARS-COV-2 infection. In addition, early intervention targeting at HBP to improve the prognosis of severe COVID-19 patients warrants clinical investigation. However, this study has its limitations. The sample size of this study is small. Because HBP has a short half-life and is affected by white blood cells during detection, its detection needs to be done in fresh serum. For these reasons, we are still lack of solid data about the sensitivity and specificity of HBP assay in severe COVID-19. Further study is also warranted to confirm our conclusions about its clinical applications. HBP is stored in vesicles in PMN near the cell membrane and is released when they are activated. HBP binds to and internalizes the surface polysaccharide receptor of endothelial cells to activate protein kinase C (PKC) and Pho kinase (PhoK) [53] . PKC in turn activates voltage-gated calcium channels, facilitating Ca2+ influx, increasing concentrations of which result in altered actin alignment and PKC also phosphorylates cytoskeletal proteins directly and causes contraction [54] . 

Improved Molecular Diagnosis of COVID-19 by the Novel, Highly Sensitive and Specific COVID-19-RdRp/Hel Real-Time Reverse Transcription-PCR Assay Validated In Vitro and with Clinical Specimens

Virology, Epidemiology, Pathogenesis, and Control of COVID-19

World Health Organization declares global emergency: A review of the

The pathogenesis and treatment of the `Cytokine Storm

Recurrence of positive SARS-CoV-2 RNA in COVID-19: A case report

Rapidly fatal outcome of Covid-19 after successful emergency surgery during pandemic outbreak in Northern Italy

Presumed asymptomatic carrier transmission of COVID-19

Genetic susceptibility for COVID-19-associated sudden cardiac death in African Americans

The reproductive number of COVID-19 is higher compared to SARS coronavirus

Marked Up-Regulation of ACE2 in Hearts of Patients With Obstructive Hypertrophic Cardiomyopathy: Implications for SARS-CoV-2-Mediated COVID-19

Recurrence of positive SARS-CoV-2 in patients recovered from COVID-19

Recurrence of COVID-19 after recovery: a case report from Italy

The severe acute respiratory syndrome

Severe Acute Respiratory Syndrome (SARS)

International congress -Reanimation

Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19)

Heparin-binding protein: a key player in the pathophysiology of organ dysfunction in sepsis

Secretion of heparin-binding protein from human neutrophils is determined by its localization in azurophilic granules and secretory vesicles

Heparin-binding protein (HBP/CAP37): a missing link in neutrophilevoked alteration of vascular permeability

A Promising Candidate: Heparin-Binding Protein Steps onto the Stage of Sepsis Prediction

Neutrophil primary granule proteins HBP and HNP1-3 boost bacterial phagocytosis by human and murine macrophages

Heparin-binding protein as a biomarker of post-injury sepsis in trauma patients

Usefulness of the heparinbinding protein level to diagnose sepsis and septic shock according to Sepsis-3 compared with procalcitonin and C reactive protein: a prospective cohort study in China

Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients

Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19

Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebocontrolled trial

Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial

Prompt Predicting of Early Clinical Deterioration of Moderate-to-Severe COVID-19 Patients: Usefulness of a Combined Score Using IL-6 in a Preliminary Study

Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19

Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19)

Sepsis and Nosocomial Infection: Patient Characteristics

Cross-correlation between spine and hip joint kinematics differs in healthy individuals and subgroups of ankylosing spondylitis patients during trunk lateral flexion

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan

Endothelial cell infection and endotheliitis in COVID-19

Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID-19)

Liver injury in COVID-19: management and challenges

Autopsy in suspected COVID-19 cases

Autopsy Findings and Venous Thromboembolism in Patients With COVID-19

The impact of nutrition on COVID-19 susceptibility and long-term consequences

Could Intravenous Immunoglobulin Collected from Recovered Coronavirus Patients Protect against COVID-19 and Strengthen the Immune System of New Patients?

COVID-19: The Inflammation Link and the Role of Nutrition in Potential Mitigation

and immune checkpoint inhibitors: initial considerations

Expansion of myeloid-derived suppressor cells in patients with severe coronavirus disease

IL-6: from its discovery to clinical applications

Essential role for IL-6 in postresuscitation inflammation in hemorrhagic shock

Translating IL-6 biology into effective treatments

IL-6: Relevance for immunopathology of SARS-CoV-2

2019-novel Coronavirus severe adult respiratory distress syndrome in two cases in Italy: An uncommon radiological presentation

Double-Hit-Induced Leukocyte Extravasation Driven by Endothelial Adherens Junction Destabilization

Effects of heparin-binding protein (CAP37/azurocidin) in a porcine model of Actinobacillus pleuropneumoniae-induced pneumonia

The Cytoskeleton as a Modulator of Aging and Neurodegeneration

Heparin-binding protein is important for vascular leak in sepsis

Evolving mechanisms of vascular smooth muscle contraction highlight key targets in vascular disease

Protein Kinase C as Regulator of Vascular Smooth Muscle Function and Potential Target in Vascular Disorders

Association Between Hypoxemia and Mortality in Patients With COVID-19

Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19

COVID-19: the vasculature unleashed

Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19)

COVID-19 and the cardiovascular system

COVID-19 and the Heart

Heparin-binding protein is important for vascular leak in sepsis

Heparin-binding protein (HBP): a causative marker and potential target for heparin treatment of human sepsis-induced acute kidney injury

SARS-CoV-1, MERS-CoV and lessons from the past

The authors would like to express their gratitude to EditSprings (https://www.editsprings.com/) for the expert linguistic services provided. At the same time, the authors also appreciated the YuanGuJi Tchnology Co.,Ltd for the technical support.

The study was approved by the Ethics Committee of the First Affiliated Hospital of Guangzhou Medical University (2020-77).